 |
|
|
| |
W48 Response Rate of Boceprevir-PegIFN-RBV in Treatment-Experienced HIV Coinfected Patients with HCV genotype 1: ANRS-HC27 BocepreVIH Study
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
Isabelle Poizot-Martin1, Eric Bellissant2, Lionel Piroth3, Alain Renault2, Marc Bourliere4, Philippe Halfon5, Caroline Solas6, Bruno Lacarelle6, Philippe Colson7, Rodolphe Garraffo8, Jean-Michel Molina9
the ANRS HC27 BOCEPREVIH Study Group
1.Immuno-Hematological Clinical Unit, Aix Marseille University, APHM Sainte-Marguerite,Inserm U912 (SESSTIM) , Marseille, France.
2. Department of Clinical Pharmacology, Rennes 1 University, Rennes, France. Rennes University Hospital,INSERM 0203 CIC-P Clinical Investigation Centre, Rennes, France.
3. Infectious Diseases Department, University Hospital, Dijon, France.
4. Hepato-Gastro-Enterology unit, Hopital Saint- Joseph, Marseille, France.
5. Medical Clinical Unit, Hopital Ambroise Pare, Marseille, France.
6. Pharmacokinetic and toxicology unit, Aix Marseille Univ, APHM Timone, CRO2 INSERM U911, Marseille, France.
7. Federation de Microbiologie Hospitaliere, Aix Marseille University, AP-HM Timone,URMITE UM 63 CNRS 7278 IRD 198 INSERM 1095, Marseille, France.
8. Pharmacology Unit, Faculty of Medecine of Nice, Hopital Pasteur, , Marseille, France.
9. Infectious Diseases Unit, Paris VII - Denis Diderot University,Assistance Publique Hopitaux de Paris (AP-HP) - Saint-Louis Hospital , Paris, France.
|
| |
|
|
|
|
|
